Sanofi, the Healthcare sector company, was revisited by a Wall Street analyst on July 31. Analyst David Risinger from Leerink Partners maintained a Buy rating on the stock and has a €92.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors influencing Sanofi’s stock. Despite lowering the price target to €92 from €101, Risinger sees attractive valuation in Sanofi’s shares, which closed at a 2026 estimated P/E of 9.8x. This is considered appealing given the absence of significant loss of exclusivity events until 2033. Additionally, upcoming Phase 3 trial results for amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis present potential catalysts for the stock.
Risinger also notes adjustments in the financial model, including a reduction in the 2025 revenue forecast by 2% and a 5% decrease in EPS estimates, reflecting updated foreign exchange assumptions and increased R&D and SG&A expenses due to recent acquisitions. Despite anticipated financial headwinds from the winding down of the Dupixent collaboration reimbursement, the expected ramp-up in Amvuttra royalties in 2027 provides a partial counterbalance. These factors collectively support the Buy rating for Sanofi’s stock.
In another report released on August 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €89.00 price target.
SNYNF’s price has also changed moderately for the past six months – from $108.368 to $92.600, which is a -14.55% drop .